While neither warning is classified as a recall, the FDA has provided additional information for the two products. Boston ...

The FDA has issued an alert regarding a safety concern with certain Boston Scientific defibrillator leads used in implantable cardioverter defibrillators. The affected models include Endotak Reliance, ...

U.S. health officials have issued warnings on two separate Boston Scientific heart devices recently linked to injuries and ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth ...

Boston Scientific’s AI leadership, global growth, and strong R&D make it a long-term winner despite valuation and regulatory ...

The FDA is reviewing Boston Scientific's defibrillator leads after reports of rising shock impedance and 16 related deaths.

Boston Scientific has updated the instructions for use for products deployed in the implantation of its Watchman heart device ...

Marlborough, Mass.-based Boston Scientific’s new Endura Weight Loss Solutions offers minimally invasive procedures for patients who want alternatives to diet, medication and bariatric surgery.

Boston Scientific (BSX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Boston Scientific warned of the potential for rising low-voltage shock impedance (LVSI) associated with Reliance ...

Boston Scientific improved B2B search experiences by integrating AI-enabled search from Coveo into their SAP Commerce Cloud stack.

Looking further ahead, Boston Scientific expects full-year 2025 EPS in the range of $2.95 to $2.99, above the $2.92 consensus. 3rd party Ad. Not an offer or recommendation by Investing.com.